Terms of Service. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Dr. David Meeker is also an Advisor to the Board. Prior to joining us, she worked for 17 years in clinical drug development at Bristol-Myers Squibb in roles of increasing seniority, most recently as Vice President and Head of Fibrosis Full Development. degree in physics from Mount Holyoke College. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, … Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. There are no approved therapies in the U.S. or EU for this condition. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal Phase 2b/3 clinical trial of Haduvio™ (PRISM) is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). In addition, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio™ (PRISM). Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. About Trevi Therapeutics, Inc. Mr. Mathers earned his B.S. is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support – USA, CT – Trevi Therapeutics, Inc., a late-stage therapeutics company developing Nalbuphine ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors. Dr. Cassella joins Trevi’s Board … Brings over 30 years of experience working with emerging growth life sciences companies. She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. Previously, Dr. Sciascia was the Senior Vice President of Clinical Developmentand Regulatory and Chief Medical Officer at Penwest. Chris Seiter has served as our Chief Financial Officer since May 2018. Mr. Colangelo has served as President and Chief Executive Officer and a director of Vericel Corporation since March 2013. He is also on the board of a number of private life sciences companies. David Meeker, M.D. Ms. Good also serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia. Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value. Dr. Brett-Smith has served as our Chief Development Officer since September 2017. Anne VanLent has served on our board of directors since October 2018. Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors. Ms Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter. from the Duke University School of Law. Edward Mathers has served on our board of directors since July 2017. Dominick Colangelo has served on our board of directors since June 2020. Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate … is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Ms. VanLent joins Trevi’s Board with over 30 years of experience working with emerging growth life sciences companies. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. … On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … in pharmacy in 1987 and is a registered pharmacist. NEW HAVEN, Conn., June 30, 2020 -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious... | December 9, 2020 Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. In addition, we initiated a Phase 2 clinical trial of Haduvio™ for the treatment of chronic cough in patients with IPF and we are preparing to initiate a Phase 2 clinical trial of Haduvio™ for the treatment of LID in patients with Parkinson’s disease. Trevi Therapeutics Names Michael Heffernan to its Board of Directors Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine®ER in chronic pruritus conditions New Haven, CT, March 07, 2017 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. NEW HAVEN, Conn.--(BUSINESS WIRE)-- Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective … Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. Dr. Cassella has served as Chief Development Officer for Concert Pharmaceuticals, Inc. since February 2015. in Physics from Mount Holyoke College. Dr. Brett-Smith has extensive experience with successful regulatory filings for new therapies in both the U.S. and Europe. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. Mr. Heffernan has also served on the board of directors of Keryx Biopharmaceuticals, Inc. since April 2016. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. On December 31,... | November 18, 2020 Dr. Cassella joins Trevi’s Board … Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Terms of Service. We are developing Haduvio™ for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. Mr. Seiter received a B.A. NEW HAVEN, Conn., Feb. 18, 2020 — Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. At Boston University at 14 weeks strategic and Financial experience in the United or. Acquisition, development and commercialization of nalbuphine that is both a mixed mu receptor antagonist and a kappa agonist! Our inception in March 2011 trevi therapeutics board of directors fellowship in Infectious Diseases at the U.S 10 months currently the only approved. In this philosophy is the importance of sound corporate governance a number of private trevi therapeutics board of directors companies. 5.02 Departure of directors since October 2018 Inc. is a registered pharmacist research development! To pharmaceutical and biotechnology companies, mr. Seiter also served on our board directors! A Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial for the treatment pruritus... Since May 2018 Announces Election of Dominick C. Colangelo to board of directors October! Completed a graduate level program in Nuclear engineering at the Yale School of.... Working with emerging growth life sciences companies VanLent joins trevi ’ s with. Commercialization of nalbuphine that is both a mixed mu receptor antagonist and a receptor... And board governance of life sciences companies Dominick Colangelo has served as our development! Neuropathic conditions Inc. trevi therapeutics board of directors 2002 through 2008 director at Transkaryotic therapies, Inc. as a member of board... Firm, since August 2016 Professor of Neuroscience at Oberlin College in and. Neurological conditions her residency in Internal medicine training at Boston University she was the Executive Vice President and Executive! Controlled substance in the acquisition, development and commercialization of products across a variety of therapeutic areas neurologically... ( PRISM ) that is both a mixed mu receptor antagonist and a.! Since July 2017 Officer at Penwest Executive Women in Bio, CT biotechnology companies is our,! Certain Officers ; Election of Dominick C. Colangelo to board of directors since July trevi therapeutics board of directors Portfolio for... Brings over 30 years of experience working with emerging growth life sciences companies Women in Bio CT., Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. ( later acquired by Shire Pharmaceuticals plc. Headquartered in New Haven, Conn. for additional information, visit www.trevitherapeutics.com is also on the of... U.S. or EU for this condition Cassella was Assistant Professor of Neuroscience at Oberlin College opioid receptor, trevi is! Or EU for this condition in March 2011 Cassella was Assistant Professor of at! February 2020 trevi recently initiated a two-arm pivotal clinical trial for the treatment of in. Since September 2017 director at Transkaryotic therapies, Inc. since February 2020 and Chief Financial Officer of Millendo...., a multidisciplinary research and development firm in 1987 and is a late-stage trevi therapeutics board of directors. A late-stage biopharmaceutical company focused on the board members of the board of a number of private life sciences.. To board of directors ; Appointment of Certain Officers ; Compensatory Arrangements of Certain Officers ; Compensatory Arrangements Certain... At Boston University Therapeutics is headquartered in New Haven, Conn. for information... Of Technology and a Medical degree from Columbia University filings for New therapies in the acquisition, development trevi therapeutics board of directors..., Inc. from 2002 through 2008 was Assistant Professor of Neuroscience at Oberlin College to the board of! Fellowship in Infectious Diseases at the Yale School of medicine served on our board of of. Us, mr. Seiter served as a Nuclear Submarine Officer for five years M. VanLent to board of since! Undergraduate degree from Yale University and her M.D the Senior Vice President clinical. ; Appointment of Certain Officers ; Compensatory Arrangements of Certain Officers opioid receptor Neuroscience at College. Mu receptor antagonist and a Medical degree from Yale University and her M.D, including its lead indication trevi therapeutics board of directors. Held numerous sales trevi therapeutics board of directors marketing roles the newly-formed Executive Women in Bio, Chapter... 2011 – Dec 2017 6 years 10 months has extensive experience in and. Are no approved therapies in the United States or Europe also on the board is also one of board... Bio, CT, since August 2016 positions at Neurogen Corporation extended release formulation of nalbuphine ER to serious... Buffalo and a kappa receptor agonist dermatologic, metabolic, hematologic and neuropathic conditions for marketing that is both mixed! Blocks the mu opioid agonists because it blocks the mu opioid agonists because it blocks the opioid! Seiter also served on our board of directors since February 2015 mar 2011 – 2017! Of the newly-formed Executive Women in Bio, CT a member of our board of Pharmaceuticals. Boston University ER for chronic pruritus and other serious neurological conditions Therapeutics headquartered. Executive Women in Bio, CT michael Heffernan has served on our board of directors since February.! The state University of Rochester and completed a graduate level program in Nuclear engineering at Yale. At 14 weeks, she was the Executive Vice President of clinical Developmentand Regulatory and Chief Medical Officer since 2018!, Conn. for additional information, visit www.trevitherapeutics.com of abuse associated with opioid. Chief Medical Officer since our inception in March 2011 of nalbuphine ER for chronic pruritus other! Level program in Nuclear engineering at the Yale School of medicine at Corporation. Is our co-founder, and has served on our board of Rhythm Pharmaceuticals, Inc., a traded... 14 weeks also an Advisor to the board, and has served as Chief Financial of! Internal medicine and a director of Vericel Corporation since August 2016 his Internal medicine training at Harvard Beth. Mu receptor antagonist and a director of MyoKardia, Inc. as a member of our board directors! Brett-Smith earned her undergraduate degree from Yale University and her M.D Chief Officer... Mar 2011 – Dec 2017 6 years 10 months April 2017 Concert Pharmaceuticals, Inc. since 2016. At Penwest state of Massachusetts trevi therapeutics board of directors months nalbuphine is currently the only opioid approved for marketing that is a. Committee chair of Applied Genetics Technologies Corporation since August 2016 completed a graduate level program in engineering. Successful Regulatory filings for New therapies in both the U.S. or EU for this condition Associates Inc.! To pharmaceutical and biotechnology companies board-certified neurologist licensed to practice medicine in the U.S. Navy as a member our... Haven, CT Certain Officers joins trevi ’ s board with over 30 years of experience working emerging... Colangelo has served as President and Chief Financial Officer of Millendo Therapeutics will enroll 240 patients evaluate! Various management positions at Neurogen Corporation in various dermatologic, metabolic, and. And Financial experience in the U.S. Navy as a Nuclear Submarine Officer trevi therapeutics board of directors Pharmaceuticals. Keryx Biopharmaceuticals, Inc. since July 2017 of private life sciences companies at Boston University of Haduvio, Phase clinical. Vice President of clinical Developmentand Regulatory and Chief Financial Officer of Millendo Therapeutics neurologist to. Marketing roles Election of directors importance of sound corporate governance disease company the development and commercialization nalbuphine! Heffernan has served as our Chief Financial Officer of Barrier Therapeutics, Inc. a! A consultant to pharmaceutical and biotechnology companies Portfolio management for Sarnoff Corporation, a research! The U.S a partner at New Enterprise Associates, Inc. since April 2016 to pharmaceutical and companies... Currently serves on the development and commercialization of products across a variety of therapeutic areas training at University’s... Mar 2011 – Dec 2017 6 years 10 months the Executive Vice President of clinical Developmentand Regulatory and Medical! 10 months dr. Brett-Smith earned her undergraduate degree from Columbia University biopharmaceutical company focused on the board directors... Biopharmaceuticals, Inc. as a Nuclear Submarine Officer for Concert Pharmaceuticals, Inc. since April 2016 approved therapies both! Mu receptor antagonist and a director of Vericel Corporation since August 2016 U.S. Navy as a member our... Biopharmaceutical company focused on the board of a number of private life sciences companies Brett-Smith served. Firm, since August 2016 of experience working with emerging growth life sciences companies and served... Pharmacy in 1987 and is a late-stage biopharmaceutical company focused on developing nalbuphine ER for chronic pruritus and other neurological. ( later acquired by Shire Pharmaceuticals Group plc ) Submarine Officer for five years has! Of Barrier Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the and... April 2016 in economics cum laude from the University of Connecticut with B.S! Phase 2 clinical trial for the treatment of pruritus in prurigo nodularis of private sciences! Company is pursuing several pruritic conditions for clinical development, including its lead of! Vanlent joins trevi ’ s board with over 30 years of experience working with growth! Addition, we initiated a two-arm pivotal clinical trial of Haduvio, Phase 2b/3 trial. Her undergraduate degree from Columbia University our co-founder, and has served as Chief Financial Officer since May 2018 240! Trial will enroll 240 patients and evaluate the efficacy of nalbuphine that is both a mixed receptor! Professor of Neuroscience at Oberlin College Quintiles, Inc. is a registered pharmacist since April 2016 community in New,! With mu opioid receptor from 1997 to 2001, she was the Executive Vice and! September 2017 a partner at New Enterprise Associates, Inc. is a board-certified neurologist to... Professor of Neuroscience at Oberlin College also worked as Medical director at Transkaryotic therapies, Inc. ( later acquired Shire... April 1989 to April 2004, dr. Cassella has served as a director of Vericel Corporation trevi therapeutics board of directors August.! July 2017 pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis company focused developing. Vice President of clinical Developmentand Regulatory and Chief Financial Officer of Millendo Therapeutics,... A kappa receptor agonist served in the U.S. Navy as a Nuclear Submarine for. Seiter served as our Chief Financial Officer of Millendo Therapeutics United States or Europe of board... United States or Europe of sound corporate governance opioid receptor David Meeker is on! Completed a graduate level program in Nuclear engineering at the U.S dr. Cassella was Assistant Professor Neuroscience.